Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2012-11-26 Regulatory Filings
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Commencement of Three-Month Toxicology Studies For BIT225 2 pages 51.1KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Biotron Limited regarding the commencement of three-month toxicology studies for their antiviral drug BIT225. It provides updates on preclinical studies, manufacturing, and formulation development. The document is only 2923 characters long, which is quite brief and does not contain any financial data, detailed financial statements, or comprehensive report content. It is not an annual or interim report, earnings release, or any detailed investor presentation. It is also not a regulatory certification or officer attestation. The content is a corporate update on drug development progress, which fits best under a general regulatory announcement category. Given the length and nature, it is not a full report but an announcement-type filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2012-11-26 English
Presentation of BIT225 HCV 48-week data at AASLD Conference 2 pages 953.7KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation of clinical trial data for a drug (BIT225) targeting Hepatitis C Virus (HCV). It includes extensive scientific and clinical trial results, safety and efficacy data, and pharmacokinetic information. The document is dated November 16, 2012, and references a presentation at the American Association for the Study of Liver Diseases (AASLD) 2012 annual conference. The content is focused on presenting trial results and scientific data rather than financial results or regulatory announcements. It is not an earnings release, annual report, or regulatory filing. The document is a presentation of clinical data likely intended for investors or the scientific community, consistent with an Investor Presentation (IP). The length (over 14,000 characters) and detailed data support this classification rather than a brief announcement or report publication notice.
2012-11-15 English
Key Phase 2 HIV/HCV Trial Commenced 2 pages 52.5KB
Capital/Financing Update Classification · 95% confidence The document is a short announcement (2 pages) from Biotron Limited dated 9 November 2012, describing the commencement of a Phase 2 clinical trial for their drug candidate BIT225 targeting HIV/HCV co-infected patients. It provides details about the trial design, patient population, and expected outcomes. There are no financial statements, regulatory certifications, or detailed financial data. The document is clearly an update on a clinical trial commencement, which is a form of company operational update or capital/financing activity related to drug development progress. It is not an annual report, earnings release, or any form of financial report. Given the nature of the content and the context of a clinical trial start announcement, the most appropriate classification is Capital/Financing Update (CAP), as it relates to the company's development activities and potential future capital implications. The document length is short and does not indicate it is a report publication announcement or regulatory filing. Confidence is high due to clear content focus on trial commencement and company update.
2012-11-08 English
Presentation to Investors 16 pages 253.7KB
Investor Presentation Classification · 95% confidence The document is a PowerPoint presentation delivered by the CEO of Biotron Limited to investors, as explicitly stated in the cover letter. It contains detailed information about the company's clinical drug development pipeline, recent financial highlights, market context, and future plans. The content is typical of an investor presentation focusing on financials, strategy, and market position. The document is not an official report like an annual or interim report, nor is it a regulatory filing or announcement. It is a presentation material intended for investors, matching the definition of an Investor Presentation (IP). The document length (10,231 characters) supports it being a full presentation rather than a brief announcement or certification.
2012-10-25 English
Annual Report and Notice of AGM 57 pages 1.2MB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT AND NOTICE OF AGM' and explicitly states it is the company's Annual Report for the year ended 30 June 2012. It contains detailed sections typical of an annual report, including Operating and Financial Review, Directors' Report, Auditor's Report, and full financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial and operational details, clinical program updates, and corporate governance information, consistent with an Annual Report (10-K) filing. Therefore, the document is classified as an Annual Report (10-K). FY 2012
2012-10-24 English
Appendix 4C - quarterly 5 pages 40.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash reconciliation, payments to directors, financing facilities, and compliance statements. It covers a specific quarter ending 30 September 2012. The content is substantive and includes actual financial statements and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document is not a brief announcement or a certification, but a full quarterly financial report. Q1 2013
2012-10-21 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.